This Box Keeps Donor Eyeballs Alive After Death

The first whole-eye transplant was a surgical success but a functional failure. A new perfusion device keeps donor eyes 'alive,' potentially making sight-restoring transplants a reality.

The world’s first whole-eye transplant was a surgical masterpiece. A team at NYU Langone successfully attached a donor eye to a living man. But the eye can't see. The optic nerve, once severed, refused to reboot. That’s been the wall for decades: an eyeball cut from its blood supply starts dying in minutes, long before it can be reconnected. A new device, however, might just break through that wall. It's a box that keeps eyes alive after the donor is gone, potentially turning a surgical miracle into a functional cure for blindness.

Researchers at the Barcelona Institute of Science and Technology call their prototype the "Eye-in-a-Care-Box," or ECaBox. The mechanism is perfusion, a technique used for other organs where a machine takes over for the body's circulation. In this case, a custom pump delivers an oxygenated, nutrient-rich fluid directly into the eye's central retinal artery. As detailed in a preprint article on bioRxiv, this process keeps the delicate structures of the retina from collapsing. The team first proved this on pig eyes, which otherwise decayed within 24 hours even when cooled. In the ECaBox, they not only stayed structurally sound but regained their ability to respond to light for up to 10 hours—a basic electrical sign of life that vanishes almost immediately after removal.

The immediate winner isn't a patient, but the pharmaceutical industry. The ECaBox creates a new platform for testing drugs on functional human tissue without navigating the cost and ethics of animal or human trials. This could shave millions from ophthalmology R&D budgets. The long-term play, however, challenges the entire organ transplant economy. Creating a viable method for whole-eye transplantation would spawn a new logistics chain for procurement, preservation, and surgery, benefiting specialized medical centers. It also puts pressure on developers of high-tech alternatives like retinal implants and gene therapies. If you can swap in a working biological eye for a fraction of the cost of a bionic one, the market for silicon retinas looks a lot smaller.

The team's next move is a portable ECaBox designed for the operating room, to get donor eyes on life support with near-zero delay. We won't know if this works until a perfused eye is transplanted and a patient reports sight. The May 2023 transplant, reported in JAMA, established that a donor eye could maintain healthy blood flow post-surgery, but it never fired signals to the brain. Fixing that information gap is the next five-year problem. Even if they solve it, the technology forces a difficult conversation. If you can keep organs functionally "alive" for hours or days after death, where does the donor end and the medical supply chain begin?